实用医学杂志 ›› 2022, Vol. 38 ›› Issue (4): 516-521.doi: 10.3969/j.issn.1006⁃5725.2022.04.024

• 综述 • 上一篇    下一篇

嵌合抗原受体T细胞免疫疗法治疗胰腺癌的研究进展

田静1 张之勇2 白天凯1 闫滨1   

  1. 1山东中医药大学(济南250355);2山东第一医科大学(济南250013

  • 出版日期:2022-02-25 发布日期:2022-02-25
  • 通讯作者: 闫滨 E⁃mail:robinyan2002@163.com
  • 基金资助:
    基金项目:国家卫生部重大新药创制科技重大专项子课题(编号:2014ZX09509001001);山东省医药卫生科技发展计划项目(编号:202002050626)

CAR ⁃T therapy for pancreatic cancerResearch progress and prospects

TIAN Jing*,ZHANG Zhiyong,BAI Tiankai,YAN Bin.   

  1. Shandong University of Traditional Chinese MedicineJi′nan 250355China

  • Online:2022-02-25 Published:2022-02-25
  • Contact: YAN Bin E⁃mail:robinyan2002@163.com

摘要:

胰腺癌是一种高度恶性肿瘤,近年来发病率呈逐年上升趋势。目前还没特别好的筛查、发现和治疗手段,因此迫切需要寻找新的有效安全的胰腺癌治疗方法。近年来,嵌合抗原受体 T 细胞免疫疗法(chimeric antigen receptor T⁃cell immunotherapy,CAR⁃T)在肿瘤方面取得了重大突破,作为目前有效的恶性肿瘤的治疗方式之一,CAR⁃T 细胞治疗效果可持续数年,趋向于长期抗肿瘤记忆,可有效预防复发。该技术进步很快,新的进展几乎以月为单位出现,胰腺癌的根治可能会有实质改善。本文就 CAR⁃T 的基本组成、胰腺癌的热门靶点及其面临的主要挑战做出简单的概述,并总结了近期关于 CAR⁃T 研究的新进展以及解决问题的方向,为后续治疗胰腺癌提供研究思路。

关键词:

CAR?T 免疫疗法, 胰腺癌, 靶点, 挑战, 联合治疗

Abstract:

Pancreatic canceris a highly malignant tumorand its incidence has been increasing year byyear. There is currently a lack of particularly good screeningdetection and treatment approach. Thereforeit′surgent to develop and find new effective and safe treatments for pancreatic cancer. In recent yearschimeric antigenreceptor T⁃cell immunotherapyCAR⁃Thas made a major breakthrough in cancer treatment.As one of the effectivetreatment modalities for malignant tumorsthe effect of CAR⁃T cell therapy can last for several yearstending tolong ⁃term anti ⁃tumor memoryand can effectively prevent recurrence. The technology is advancing rapidlywithnew advances occurring almost on a monthly basisand eradication of pancreatic cancer may be substantiallyimproved. This article provides a brief overview of the basic components of CAR⁃Tthe popular targets for pancreaticcancer and the main challenges they faceand summarizes the recent new advances on CAR⁃T research and thedirection of problem solving to provide research ideas for the subsequent treatment of pancreatic cancer.

Key words: chimeric antigen receptor T?cell immunotherapy,  , pancreatic cancer,  , target,  , challenge, combination therapy